Crystal Lake, Illinois, October 28, 2021 — AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions, today reported third quarter results for 2021.
Third Quarter 2021 Summary
- Reported sales grew 9%, primarily driven by double-digit core sales growth in Beauty + Home and Food + Beverage from a combination of price increases and volume growth
- Core sales (excluding currency effects) increased 8%
- Pharma sales declined slightly compared to the prior year
- Reported earnings per share totaled $0.70 and included restructuring charges ($0.12), an unrealized loss on an equity investment ($0.10) resulting from the mark-to-market position of our investment in PureCycle Technologies, Inc. (purification recycling technology) and acquisition costs ($0.02)
- Adjusted earnings per share, excluding restructuring charges, the loss on the equity investment and acquisition costs, totaled $0.94
- Reported net income totaled $47 million
- Adjusted EBITDA totaled $154 million
- Acquisition Updates:
- Completed the acquisition of 80% of Weihai Hengyu Medical Products, adding elastomeric and plastic component manufacturing capabilities in China for injectable drug delivery
- Completed the acquisition of a majority stake in Voluntis, a provider of digital therapeutic solutions
